Zhang Yan, Wang Wei, Xu Lian, Huang Liujing, Qin Tian, Kang Ling, Huang Qin
Department of Pathology, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University Chengdu 610000, Sichuan, PR China.
Int J Clin Exp Pathol. 2025 May 15;18(5):179-190. doi: 10.62347/EHAI6164. eCollection 2025.
To investigate the expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in ovarian cancer tissues and its correlation with clinicopathologic features, chemotherapy sensitivity, and prognosis in patients with ovarian cancer.
Paraffin tissue blocks were collected from 227 ovarian cancer patients, and immunohistochemical (IHC) staining was performed to analyze the expression of ROR1. The associations between ROR1 expression and clinicopathologic features, treatment response, and prognosis were evaluated.
ROR1 expression and tumor load: higher expression of ROR1 was associated with a heavier tumor load in ovarian cancer patients. ROR1 and chemotherapy: the expression of ROR1 was significantly higher in patients who underwent interval debulking surgery (IDS) compared to primary debulking surgery (PDS) and subsequent chemotherapy (SSC). This suggests that chemotherapy may promote increased ROR1 expression in tumor tissues. Additionally, a trend of higher ROR1 expression was observed in platinum-sensitive patients. Nuclear expression in clear cell ovarian cancer: positive nuclear expression of ROR1 was unexpectedly detected in clear cell ovarian cancer, suggesting a link between ROR1 nuclear translocation and poor prognosis.
ROR1 expression may be related to treatment strategy and history of platinum-based chemotherapy in ovarian cancer patients. Targeting ROR1 could represent a promising therapeutic strategy for the treatment of ovarian cancer. Further studies are needed to elucidate the role of ROR1 nuclear translocation in prognosis.
探讨受体酪氨酸激酶样孤儿受体1(ROR1)在卵巢癌组织中的表达及其与卵巢癌患者临床病理特征、化疗敏感性和预后的相关性。
收集227例卵巢癌患者的石蜡组织块,采用免疫组织化学(IHC)染色分析ROR1的表达。评估ROR1表达与临床病理特征、治疗反应和预后之间的关联。
ROR1表达与肿瘤负荷:ROR1表达较高与卵巢癌患者肿瘤负荷较重相关。ROR1与化疗:与初次肿瘤细胞减灭术(PDS)及后续化疗(SSC)相比,接受间歇性肿瘤细胞减灭术(IDS)的患者ROR1表达显著更高。这表明化疗可能促进肿瘤组织中ROR1表达增加。此外,在铂敏感患者中观察到ROR1表达有升高趋势。透明细胞卵巢癌中的核表达:在透明细胞卵巢癌中意外检测到ROR1核阳性表达,提示ROR1核易位与预后不良之间存在关联。
ROR1表达可能与卵巢癌患者的治疗策略及铂类化疗史有关。靶向ROR1可能是治疗卵巢癌的一种有前景的治疗策略。需要进一步研究阐明ROR1核易位在预后中的作用。